Last Updated on August 11, 2022 by GlobeNewsWire
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at EHA successfully demonstrates in-vivo engraftment of multiplex edited HSCs for next-generation AML treatmentCash runway extended into Q1 2024
CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2022, and provided a business update.
“We are on track to disclose first-in-human clinical data for our lead product candidate VOR33 in Q4 this year,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We believe this data will provide clinical proof-of-concept for VOR33 and our proprietary platform, which has the potential to transform outcomes for patients with blood cancers.”
Vor Bio’s in-house clinical manufacturing facility in Cambridge, MA headquarters to become operational in Q4 2022. The facility is designed to support clinical manufacturing for both Vor Bio’s eHSC and CAR-T product pipeline and reduce the time and cost required to manufacture cell therapy clinical candidates.
Successfully demonstrated engraftment of multiplex edited Hematopoietic Stem Cells (HSCs). Pre-clinical data recently presented at the European Hematology Association Congress, June 9-12, demonstrated that multiplex deletion of CD33 and CLL-1 from human CD34+ hematopoietic stem and progenitor cells (HSPCs) maintained cell function and persisted long-term post engraftment in vivo, with a high-level of editing, no counterselection, and minimal translocation risk when compared to unedited control cells. In addition, genetically modifying HSPCs to remove select cell surface targets did not appear to impair function and these dual engineered cells showed significant protection from targeted immunotherapy in vitro. A link to the presentation can be found on the Company’s website at: https://www.vorbio.com/publications/
VOR33: VOR33 is the Company’s lead product candidate consisting of genome-edited HSPCs that have been engineered to lack the CD33 protein. It is designed to replace standard of care transplants for patients suffering from acute myeloid leukemia (AML) and potentially other blood cancers. VOR33 has been granted Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration.
The Company is on track to share initial clinical proof-of-concept data in Q4 of 2022 from VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of VOR33 in patients with AML who are at risk of relapse. Successful engraftment would provide important validation for Vor Bio’s platform.Patients receive Mylotarg(TM), an antibody-drug conjugate, around day 60 post-transplant. Initial data on VOR33’s ability to provide hematologic protection from Mylotarg toxicities is expected to follow shortly after initial engraftment data.The clinical trial continues to recruit patients with six trial sites currently active.The enrollment of the first three patients in VBP101 is staggered such that prior to treating the next patient, each patient must demonstrate neutrophil recovery at 28 days after Hematopoietic Cell Transplantation (HCT) and VOR33 infusion. Additionally, dose escalation of Mylotarg, which is being executed using a 3+3 design, is staggered for each of the first three patients and the first patient at each dose escalation.
VCAR33 Programs: The VCAR33 programs are chimeric antigen receptor T (CAR-T) cell therapy candidates designed to target CD33, a clinically-validated target for AML.
VCAR33ALLO uses allogeneic healthy donor-derived cells and is Vor Bio’s lead VCAR33 program in which the Company plans to submit an investigational new drug (IND) application in the first half of 2023 to support a Phase 1/2 clinical trial for patients with relapsed/refractory AML. The scientific community has an increasing appreciation for the value of stem-like cell phenotype in CAR-T approaches, and HLA-matched healthy donor cells have a potentially superior cell phenotype with improved persistence and in vivo expansion capability.
VOR33 + VCAR33 Treatment System: The combination of VOR33 followed by treatment with VCAR33 in the post-transplant setting could potentially transform patient outcomes and offer the potential for cures for patients who have limited treatment options. The VOR33 + VCAR33 Treatment System will use the same healthy donor allogenic cell source for both VOR33 and VCAR33. The Company’s development pathway is to collect initial data on VOR33 from the VBP101 clinical trial and initial clinical data from the VCAR33ALLO program prior to IND submission for this Treatment System.
VOR33-CLL1 + VCAR33-CLL1 Treatment System: The Company continues to make progress on preclinical and IND-enabling studies for its multiplex-edited program. Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using Vor Bio’s novel eHSC platform, which can be combined with a multi-specific CAR-T approach.
Initial VOR33 clinical data on-track for Q4 of 2022In-house clinical manufacturing facility on-track to be operational in Q4 2022VCAR33ALLO IND submission expected in the first half of 2023Data from the Phase 1/2 National Marrow Donor Program (NMDP)-sponsored trial evaluating VCAR33AUTO expected in 2022VOR33 + VCAR33 Treatment System IND submission expected following initial clinical data from the VBP101 clinical trial and the VCAR33ALLO program
Second Quarter 2022 Financial Results
Cash Position: Cash, cash equivalents and investments were $151.1 million as of June 30, 2022, which is anticipated to fund operations into the first quarter of 2024. Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2022 were $15.3 million, compared to $13.0 million for the second quarter of 2021. The increase in R&D expenses was primarily due to an increase in employee headcount necessary to support the growth of our R&D efforts and in facility costs and other expenses as a result of our laboratory and cGMP manufacturing facility expansion.General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2022 were $6.5 million, compared to $5.4 million for the second quarter of 2021. The increase in G&A expenses was primarily due to increases to personnel-related costs and stock-based compensation, professional fees and facility costs and other expenses as a result of our corporate headquarters office expansion.Capital Expenditures and Facility Expansion: During the second quarter of 2022, spend increased due to one-time capital expenditures and advancements related to the build-out of our laboratory and in-house clinical manufacturing facility.Net Loss: Net loss for the second quarter of 2022 was $21.7 million, compared to $18.4 million for the second quarter of 2021.
About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding its upcoming milestones, including timing with respect to initial clinical data for VOR33, submission of an IND for the VCAR33ALLO program, receipt of data from the Phase 1/2 NMDP-sponsored trial evaluating VCAR33AUTO, the submission of an IND for the VOR33 + VCAR33 Treatment System and its in-house clinical manufacturing facility being operational, as well as its cash, cash equivalents and investments, cash runway and expected capital requirements. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Condensed Consolidated Balance Sheet Data (in thousands) June 30, December 31, 2022 2021 Cash, cash equivalents and marketable securities $151,088 $207,469 Total assets 224,615 242,590 Total liabilities 49,641 26,327 Total stockholders’ equity 174,974 216,263 Condensed Consolidated Statement of Operations (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Operating expenses: Research and development $15,333 $12,970 $30,613 $21,911 General and administrative 6,459 5,410 13,979 10,199 Total operating expenses 21,792 – 18,380 – 44,592 – 32,110 Loss from operations (21,792) (18,380) (44,592) (32,110) Other income (expense): Interest income 133 10 196 17 Total other income 133 10 196 17 Net loss $(21,659) $(18,370) $(44,396) $(32,093) Cumulative dividends on redeemable convertible preferred stock – – – (1,228) Net loss attributable to common stockholders $(21,659) $(18,370) $(44,396) $(33,321) Net loss per share attributable to common stockholders, basic and diluted $(0.58) $(0.50) $(1.19) $(1.13) Weighted-average common shares outstanding, basic and diluted 37,437,063 36,843,087 37,365,647 29,593,814
Contact: Investors & Media Sarah Spencer +1 857-242-6076 email@example.com